Please Wait.....
Report
NA Liver Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-04-01 I 264 Pages I Data Bridge Market Research
The North America liver cancer diagnostics market is projected to register a substantial CAGR of 6.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
North America Liver Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the North America liver cancer diagnostics market are:
- Rise in prevalence and incidence of liver cancer in the world
- Increase in awareness about the liver cancer diagnostics
Market Players:
Some of the major players operating in the North America liver cancer diagnostics market are:
- F. Hoffmann-La Roche Ltd.
- Koninklijke Philips N.V.
- Thermo Fisher Scientific Inc.
- BD
- Siemens Healthcare GmbH
- Agilent Technologies, Inc.
- Illumina, Inc.
- QIAGEN
- FUJIFILM Corporation
- Sysmex Corporation AB
- Scitex Pte Ltd. (Subsidiary of Danaher.)
- Epigenomics AG
- Tebubio
- Fujirebio
- Diagnostic Biosystems Inc.
- Q-LINE BIOTECH PVT LTD.
- MOLGEN
- BIOCEPT, INC.
- Boditech Med Inc.
- Elabscience Biotechnology Inc.
- Hipro Biotechnology Co., Ltd.
- Altogen Biosystems
- Tosoh India Pvt. Ltd.
- ABK Biomedical Inc.
- Diazyme Laboratories, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 55
1.1 OBJECTIVES OF THE STUDY 55
1.2 MARKET DEFINITION 55
1.3 OVERVIEW OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET 55
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 58
2 MARKET SEGMENTATION 61
2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 DBMR TRIPOD DATA VALIDATION MODEL 64
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.6 MULTIVARIATE MODELLING 68
2.7 MARKET APPLICATION COVERAGE GRID 69
2.8 TEST TYPE LIFELINE CURVE 70
2.9 DBMR MARKET POSITION GRID 71
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTLE ANALYSIS 78
4.2 PORTER ANALYSIS 79
4.3 EPIDEMIOLOGY 80
5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS 81
6 INDUSTRY INSIGHTS 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 89
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER 90
7.1.3 INCREASING CASES OF LIVER CANCER 92
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS 93
7.2 RESTRAINTS 95
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS 95
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS 96
7.3 OPPORTUNITIES 96
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER 96
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS 96
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 97
7.4 CHALLENGES 98
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS 98
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 99
8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 100
8.1 OVERVIEW 101
8.2 IMAGING TEST 104
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 105
8.2.1.1 MR ANGIOGRAPHY (MRA) 105
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY 106
8.2.2 COMPUTED TOMOGRAPHY 106
8.2.3 POSITRON EMISSION TOMOGRAPHY 106
8.2.4 ULTRASOUND 106
8.2.5 OTHERS 106
8.3 GENOMIC TEST 106
8.4 BIOPSY 107
8.4.1 FINE NEEDLE ASPIRATION BIOPSY 108
8.4.2 CORE NEEDLE BIOPSY 108
8.4.3 LAPAROSCOPY 108
8.5 OTHERS 109
9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 110
9.1 OVERVIEW 111
9.2 STAGE III 114
9.3 STAGE II 115
9.4 STAGE IV 116
9.5 STAGE I 117
9.6 STAGE 0 118
10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 119
10.1 OVERVIEW 120
10.2 SECONDARY LIVER CANCER 123
10.2.1 HEMANGIOMA 124
10.2.2 HEPATIC ADENOMA 124
10.2.3 FOCAL NODULAR HYPERPLASIA 124
10.3 PRIMARY LIVER CANCER 124
10.3.1 HEPATOCELLULAR CARCINOMA (HCC) 125
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER) 125
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA 126
10.3.4 HEPATOBLASTOMA 126
11 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT 127
11.1 OVERVIEW 128
11.2 PLATFORM BASED PRODUCTS 131
11.2.1 NEXT GENERATION SEQUENCING 132
11.2.2 MICROARRAYS 132
11.2.3 PCR 132
11.2.4 OTHERS 132
11.3 INSTRUMENT BASED PRODUCTS 132
11.3.1 IMAGING 133
11.3.2 BIOPSY 133
11.4 KITS AND REAGENTS 134
11.4.1 ELISA TEST KITS 135
11.4.2 CASSETTE TEST KITS 135
11.4.3 OTHERS 135
11.5 OTHER CONSUMABLES 135
12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION 136
12.1 OVERVIEW 137
12.2 SCREENING 140
12.2.1 PLATFORM BASED PRODUCTS 141
12.2.2 INSTRUMENT BASED PRODUCTS 141
12.2.3 KITS AND REAGENTS 141
12.2.4 OTHER CONSUMABLES 141
12.3 DIAGNOSTIC AND PREDICTIVE 141
12.3.1 PLATFORM BASED PRODUCTS 142
12.3.2 INSTRUMENT BASED PRODUCTS 142
12.3.3 KITS AND REAGENTS 142
12.3.4 OTHER CONSUMABLES 143
12.4 PROGNOSTIC 143
12.4.1 PLATFORM BASED PRODUCTS 144
12.4.2 INSTRUMENT BASED PRODUCTS 144
12.4.3 KITS AND REAGENTS 144
12.4.4 OTHER CONSUMABLES 144
12.5 RESEARCH 144
12.5.1 PLATFORM BASED PRODUCTS 146
12.5.2 INSTRUMENT BASED PRODUCTS 146
12.5.3 KITS AND REAGENTS 146
12.5.4 OTHER CONSUMABLES 146
13 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 147
13.1 OVERVIEW 148
13.2 FLUORESCENT IN SITU HYBRIDIZATION 151
13.3 NEXT GENERATION SEQUENCING 152
13.4 FLUORIMMUNOASSAY 153
13.5 COMPARATIVE GENOMIC HYBRIDIZATION 154
13.6 IMMUNOHISTOCHEMICAL 155
13.7 OTHERS 156
14 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER 157
14.1 OVERVIEW 158
14.2 MALE 161
14.3 FEMALE 162
15 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER 163
15.1 OVERVIEW 164
15.2 HOSPITALS 167
15.3 DIAGNOSTIC CENTERS 168
15.4 CANCER RESEARCH CENTERS 169
15.5 AMBULATORY SURGICAL CENTERS 170
15.6 ACADEMIC INSTITUTES 171
15.7 OTHERS 172
16 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 173
16.1 OVERVIEW 174
16.2 DIRECT TENDER 177
16.3 RETAIL SALES 178
16.4 OTHERS 179
17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY REGION 180
17.1 NORTH AMERICA 181
17.1.1 U.S. 194
17.1.2 CANADA 202
17.1.3 MEXICO 210
18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 218
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 218
19 SWOT ANALYSIS 219
20 COMPANY PROFILE 220
20.1 F. HOFFMANN-LA ROCHE LTD. 220
20.1.1 COMPANY SNAPSHOT 220
20.1.2 REVENUE ANALYSIS 220
20.1.3 COMPANY SHARE ANALYSIS 221
20.1.4 PRODUCT PORTFOLIO 221
20.1.5 RECENT DEVELOPMENT 221
20.2 KONINLIJKE PHILIPS N.V. 222
20.2.1 COMPANY SNAPSHOT 222
20.2.2 REVENUE ANALYSIS 222
20.2.3 COMPANY SHARE ANALYSIS 223
20.2.4 PRODUCT PORTFOLIO 223
20.2.5 RECENT DEVELOPMENT 223
20.3 THERMO FISHER SCIENTIFIC INC. 224
20.3.1 COMPANY SNAPSHOT 224
20.3.2 REVENUE ANALYSIS 224
20.3.3 COMPANY SHARE ANALYSIS 225
20.3.4 PRODUCT PORTFOLIO 225
20.3.5 RECENT DEVELOPMENT 225
20.4 BD 226
20.4.1 COMPANY SNAPSHOT 226
20.4.2 REVENUE ANALYSIS 226
20.4.3 COMPANY SHARE ANALYSIS 227
20.4.4 PRODUCT PORTFOLIO 227
20.4.5 RECENT DEVELOPMENTS 228
20.5 SIEMENS HEALTHCARE GMBH 229
20.5.1 COMPANY SNAPSHOT 229
20.5.2 REVENUE ANALYSIS 229
20.5.3 COMPANY SHARE ANALYSIS 230
20.5.4 PRODUCT PORTFOLIO 230
20.5.5 RECENT DEVELOPMENT 230
20.6 AGILENT TECHNOLOGIES, INC. 231
20.6.1 COMPANY SNAPSHOT 231
20.6.2 REVENUE ANALYSIS 231
20.6.3 PRODUCT PORTFOLIO 232
20.6.4 RECENT DEVELOPMENTS 232
20.7 ABK BIOMEDICAL INC. 233
20.7.1 COMPANY SNAPSHOT 233
20.7.2 PRODUCT PORTFOLIO 233
20.7.3 RECENT DEVELOPMENT 233
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.) 234
20.8.1 COMPANY SNAPSHOT 234
20.8.2 REVENUE ANALYSIS 234
20.8.3 PRODUCT PORTFOLIO 235
20.8.4 RECENT DEVELOPMENT 235
20.9 ALTOGEN BIOSYSTEMS 236
20.9.1 COMPANY SNAPSHOT 236
20.9.2 PRODUCT PORTFOLIO 236
20.9.3 RECENT DEVELOPMENT 236
20.10 BIOCEPT, INC. 237
20.10.1 COMPANY SNAPSHOT 237
20.10.2 REVENUE ANALYSIS 237
20.10.3 PRODUCT PORTFOLIO 238
20.10.4 RECENT DEVELOPMENT 238
20.11 BODITECH MED INC. 239
20.11.1 COMPANY SNAPSHOT 239
20.11.2 PRODUCT PORTFOLIO 239
20.11.3 RECENT DEVELOPMENTS 239
20.12 DIAGNOSTIC BIOSYSTEMS INC. 240
20.12.1 COMPANY SNAPSHOT 240
20.12.2 PRODUCT PORTFOLIO 240
20.12.3 RECENT DEVELOPMENT 240
20.13 DIAZYME LABORATORIES, INC. 241
20.13.1 COMPANY SNAPSHOT 241
20.13.2 PRODUCT PORTFOLIO 241
20.13.3 RECENT DEVELOPMENT 241
20.14 ELABSCIENCE BIOTECHNOLOGY INC. 242
20.14.1 COMPANY SNAPSHOT 242
20.14.2 PRODUCT PORTFOLIO 242
20.14.3 RECENT DEVELOPMENT 242
20.15 EPIGENOMICS AG 243
20.15.1 COMPANY SNAPSHOT 243
20.15.2 REVENUE ANALYSIS 243
20.15.3 PRODUCT PORTFOLIO 244
20.15.4 RECENT DEVELOPMENT 244
20.16 FUJIFILM CORPORATION 245
20.16.1 COMPANY SNAPSHOT 245
20.16.2 REVENUE ANALYSIS 245
20.16.3 PRODUCT PORTFOLIO 246
20.16.4 RECENT DEVELOPMENT 246
20.17 FUJIREBIO 247
20.17.1 COMPANY SNAPSHOT 247
20.17.2 PRODUCT PORTFOLIO 247
20.17.3 RECENT DEVELOPMENTS 247
20.18 HIPRO BIOTECHNOLOGY CO., LTD. 248
20.18.1 COMPANY SNAPSHOT 248
20.18.2 PRODUCT PORTFOLIO 248
20.18.3 RECENT DEVELOPMENT 248
20.19 ILLUMINA, INC. 249
20.19.1 COMPANY SNAPSHOT 249
20.19.2 REVENUE ANALYSIS 249
20.19.3 PRODUCT PORTFOLIO 250
20.19.4 RECENT DEVELOPMENTS 251
20.20 MOLGEN 252
20.20.1 COMPANY SNAPSHOT 252
20.20.2 PRODUCT PORTFOLIO 252
20.20.3 RECENT DEVELOPMENT 252
20.21 QIAGEN 253
20.21.1 COMPANY SNAPSHOT 253
20.21.2 REVENUE ANALYSIS 253
20.21.3 PRODUCT PORTFOLIO 254
20.21.4 RECENT DEVELOPMENT 254
20.22 Q-LINE BIOTECH PVT LTD. 255
20.22.1 COMPANY SNAPSHOT 255
20.22.2 PRODUCT PORTFOLIO 255
20.22.3 RECENT DEVELOPMENT 255
20.23 SYSMEX CORPORATION 256
20.23.1 COMPANY SNAPSHOT 256
20.23.2 REVENUE ANALYSIS 256
20.23.3 PRODUCT PORTFOLIO 257
20.23.4 RECENT DEVELOPMENT 257
20.24 TEBUBIO 258
20.24.1 COMPANY SNAPSHOT 258
20.24.2 PRODUCT PORTFOLIO 258
20.24.3 RECENT DEVELOPMENT 258
20.25 TOSOH INDIA PVT. LTD. 259
20.25.1 COMPANY SNAPSHOT 259
20.25.2 PRODUCT PORTFOLIO 259
20.25.3 RECENT DEVELOPMENT 259
21 QUESTIONNAIRE 260
22 RELATED REPORTS 264
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security